Liposomal propranolol for treatment of infantile hemangioma at compounding pharmacies

References

• Tan X, Guo S, Wang C. Propranolol in the treatment of infantile hemangiomas. Clin Cosmet Investig Dermatol. 2021;14:1155–1163. doi: 10.2147/CCID.S332625.
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C, Prey S, Ezzedine K. Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities: Infantile haemangioma: pathophysiology and clinical aspects. J Eur Acad Dermatol Venereol. 2011;25(11):1245–1253. doi: 10.1111/j.1468-3083.2011.04102.x.
   PubMed Web of Science ®Google Scholar
• Harter N, Mancini AJ. Diagnosis and management of infantile hemangiomas in the. Pediatr Clin North Am. 2019;66(2):437–459. doi: 10.1016/j.pcl.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85–94. doi: 10.1016/S0140-6736(16)00645-0.
   PubMed Web of Science ®Google Scholar
• Kleiman A, Keats EC, Chan NG, et al. Evolution of hemangioma endothelium. Exp Mol Pathol. 2012;93(2):264–272. doi: 10.1016/j.yexmp.2012.04.020.
   PubMed Web of Science ®Google Scholar
• Xu W, Zhao H. Management of infantile hemangiomas: Recent advances. Front Oncol. 2022;12(12):1064048. doi: 10.3389/fonc.2022.1064048.
   PubMedGoogle Scholar
• Macca L, Altavilla D, Di Bartolomeo L, et al. Update on treatment of infantile hemangiomas: What’s new in the last five years? Front Pharmacol. 2022;13(13):879602. doi: 10.3389/fphar.2022.879602.
   PubMedGoogle Scholar
• Farzam K, Jan ABB. [Updated 2023 Aug 22]. In: StatPearls [online]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532906/. [Accessed 5 July 2023].
   Google Scholar
• Kovačević M, et al. Topical propranolol cream in treatment of superficial infantile hemangiomas: a literature review and 4 years of clinical experience. Acta Dermatovenerologica Alpina, Pannonica et Adriatica. 2014;23:75–78. doi: 10.15570/actaapa.2014.18.
   PubMedGoogle Scholar
• Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–2651. doi: 10.1056/NEJMc0708819.
   PubMed Web of Science ®Google Scholar
• Leung AKC, Leong KF, Lam JM. An ulcerated giant segmental hemangioma resulting in contracture of the left elbow. Paediatr Child Health. 2021;26(2):e70–e72. doi: 10.1093/pch/pxaa050.
   PubMed Web of Science ®Google Scholar
• McCuaig CC, Cohen L, Powell J, et al. Therapy of ulcerated hemangiomas. J Cutan Med Surg. 2013;17(4):233–242. doi: 10.2310/7750.2012.12037.
   PubMed Web of Science ®Google Scholar
• Mussa A, Baldassarre G, Rosaia De Santis L, et al. Four new cases of PHACES syndrome: variable phenotypic expression and endocrine features. Acta Paediatr. 2008;97(12):1729–1733. doi: 10.1111/j.1651-2227.2008.01032.x.
   PubMed Web of Science ®Google Scholar
• Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas: Topical propranolol for infantile hemangiomas. Pediatr Dermatol. 2012;29(2):154–159. doi: 10.1111/j.1525-1470.2011.01615.x.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zuo T, Chang M, et al. Propranolol hydrochloride-loaded liposomal gel for transdermal delivery: Characterization and in vivo evaluation. Int J Pharm. 2015;487(1-2):135–141. doi: 10.1016/j.ijpharm.2015.04.023.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhu X, Liu D, et al. Continuous delivery of propranolol from liposomes-in-microspheres significantly inhibits infantile hemangioma growth. Int J Nanomedicine. 2017;12:6923–6936. doi: 10.2147/IJN.S137634.
   PubMed Web of Science ®Google Scholar
• Jiang C, Ma R, Jiang X, et al. A transfersomes hydrogel patch for cutaneous delivery of propranolol hydrochloride: formulation, in vitro, ex vivo and in vivo studies. J Liposome Res. 2023;33(3):258–267. doi: 10.1080/08982104.2022.2162539.
   PubMed Web of Science ®Google Scholar
• Teaima MH, Eltabeeb MA, El-Nabarawi MA, et al. Utilization of propranolol hydrochloride mucoadhesive invasomes as a locally acting contraceptive: in-vitro, ex-vivo, and in-vivo evaluation. Drug Deliv. 2022;29(1):2549–2560. doi: 10.1080/10717544.2022.2100514.
   PubMed Web of Science ®Google Scholar
• Younis MK, Elakkad YE, Fakhr Eldeen RR, et al. Propranolol-Loaded trehalosome as antiproliferative agent for treating skin cancer: Optimization, cytotoxicity, and in silico studies. Pharmaceutics. 2023;15(8):2033. doi: 10.3390/pharmaceutics15082033.
   PubMed Web of Science ®Google Scholar
• Padula C, Nicoli S, Pescina S, et al. The influence of formulation and excipients on propranolol skin permeation and retention. Biomed Res Int. 2018;2018:1281673. doi: 10.1155/2018/1281673.
   PubMed Web of Science ®Google Scholar
• Falconer JR, Steadman KJ. Extemporaneously compounded medicines. Aust Prescr. 2017;40(1):5–8. doi: 10.18773/austprescr.2017.001.
   PubMedGoogle Scholar
• Lipoid GmbH 2022 (online). Ludwigshafen: TDS of Lipoid Liposome® 0041. Available from: https://lipoid.com/en/products/phospholipid-systems/liposomes/. [Accessed 5 Jul 2023].
   Google Scholar
• Al-Majed AA, et al. 2017. Propranolol. in: H.G. Brittain ed. Profiles of drug substances, excipients and related methodology. Cambridge: Academic Press, 42, 287–338. doi: 10.1016/bs.podrm.2017.02.006.
   Google Scholar
• Liakopoulou A, Mourelatou E, Hatziantoniou S. Exploitation of traditional healing properties, using the nanotechnology’s advantages: the case of curcumin. Toxicol Rep. 2021;8:1143–1155. doi: 10.1016/j.toxrep.2021.05.012.
   PubMed Web of Science ®Google Scholar
• Siakavella IK, Lamari F, Papoulis D, et al. Effect of plant extracts on the characteristics of silver nanoparticles for topical application. Pharmaceutics. 2020;12(12):1244. doi: 10.3390/pharmaceutics12121244.
   PubMed Web of Science ®Google Scholar
• Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372. doi: 10.3390/molecules27041372.
   PubMed Web of Science ®Google Scholar
• Antimisiaris SG, Marazioti A, Kannavou M, et al. Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev. 2021;174:53–86. doi: 10.1016/j.addr.2021.01.019.
   PubMed Web of Science ®Google Scholar
• Dhiman N, Sarvaiya J, Mohindroo P. A drift on liposomes to proliposomes: recent advances and promising approaches. J Liposome Res. 2022;32(4):317–331. doi: 10.1080/08982104.2021.2019762.
   PubMed Web of Science ®Google Scholar
• Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57. doi: 10.3390/pharmaceutics10020057.
   PubMed Web of Science ®Google Scholar
• Cheung CCL, Al-Jamal WT. Sterically stabilized liposomes production using staggered herringbone micromixer: Effect of lipid composition and PEG-lipid content. Int J Pharm. 2019;566:687–696. doi: 10.1016/j.ijpharm.2019.06.033.
   PubMedGoogle Scholar
• Gordillo-Galeano A, Mora-Huertas CE. Hydrodynamic diameter and zeta potential of nanostructured lipid carriers: Emphasizing some parameters for correct measurements. Colloids Surf, A. 2021;620:126610. doi: 10.1016/j.colsurfa.2021.126610.
   Google Scholar
• Németh Z, Csóka I, Semnani Jazani R, et al. Quality by Design-Driven zeta potential optimisation study of liposomes with charge imparting membrane additives. Pharmaceutics. 2022;14(9):1798. doi: 10.3390/pharmaceutics14091798.
   PubMed Web of Science ®Google Scholar
• USP, 〈795〉PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS. The United States Pharmacopeial Convention, Revision Bulletin. Official May 1, 2020 online). Available from: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc-795-rb-notice-20200424.pdf. [Accessed 5 Jul 2023].
   Google Scholar
• Bruschi ML, ed., 2015. Mathematical models of drug release. in Strategies to modify the drug release from pharmaceutical systems., Cambridge: Woodhead Publishing. doi: 10.1016/B978-0-08-100092-2.00005-9.
   Google Scholar
• Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-Fickian release from non swellable devices in the form of slabs, spheres, cylinders or discs. J Controlled Release. 1987;5(1):23–36. doi: 10.1016/0168-3659(87)90034-4.
   Google Scholar
• Kumar L, Utreja P. Oleic acid vesicles for transdermal delivery of propranolol hydrochloride: Development and characterization. CDTH. 2020;15(3):238–248. doi: 10.2174/1574885514666190722164119.
   Google Scholar
• Zakir F, Vaidya B, Goyal AK, et al. Development and characterization of oleic acid vesicles for the topical delivery of fluconazole. Drug Deliv. 2010;17(4):238–248. doi: 10.3109/10717541003680981.
   PubMed Web of Science ®Google Scholar
• Carrer V, Alonso C, Pont M, et al. Effect of propylene glycol on the skin penetration of drugs. Arch Dermatol Res. 2020;312(5):337–352. doi: 10.1007/s00403-019-02017-5.
   PubMed Web of Science ®Google Scholar